G
Giorgio Perilongo
Researcher at University of Padua
Publications - 194
Citations - 7553
Giorgio Perilongo is an academic researcher from University of Padua. The author has contributed to research in topics: Hepatoblastoma & Medicine. The author has an hindex of 47, co-authored 185 publications receiving 6604 citations.
Papers
More filters
Journal ArticleDOI
Whole-Brain Irradiation and Decline in Intelligence: The Influence of Dose and Age on IQ Score
Jeffrey H. Silber,Jerilynn Radcliffe,Virginia C. Peckham,Giorgio Perilongo,Priya S. Kishnani,Moshe Fridman,Joel W. Goldwein,Anna T. Meadows +7 more
TL;DR: One can forecast final IQ score based on the initial IQ score, dose of irradiation, and age at time of irradiations, and the findings should aid in the selection of appropriate therapy when whole-brain irradiation is needed.
Journal ArticleDOI
Cisplatin versus cisplatin plus doxorubicin for standard-risk hepatoblastoma
Giorgio Perilongo,Rudolf Maibach,Elisabeth Shafford,Laurence Brugières,Penelope Brock,Bruce Morland,Beatriz de Camargo,Jozsef Zsiros,Derek J. Roebuck,Arthur Zimmermann,Daniel C. Aronson,Margaret Childs,Eva Widing,Véronique Laithier,Jack Plaschkes,Jon Pritchard,Marcello Scopinaro,Gordon A. MacKinlay,Piotr Czauderna +18 more
TL;DR: Cisplatin monotherapy achieved similar rates of complete resection and survival among children with standard-risk hepatoblastoma and doxorubicin can be safely omitted from the treatment of standard- risk hepatoblowlastoma.
Journal ArticleDOI
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
Rebecka L. Meyers,Rudolf Maibach,Eiso Hiyama,Beate Häberle,Mark Krailo,Arun Rangaswami,Daniel C. Aronson,Marcio H. Malogolowkin,Giorgio Perilongo,Dietrich von Schweinitz,Marc Ansari,Dolores Lopez-Terrada,Yukichi Tanaka,Rita Alaggio,Ivo Leuschner,Tomoro Hishiki,Irene Schmid,Kenichiro Watanabe,Kenichi Yoshimura,Yurong Feng,Eugenia Rinaldi,Davide Saraceno,Marisa Derosa,Piotr Czauderna +23 more
TL;DR: A unified global approach to risk stratification in children with hepatoblastoma is created on the basis of rigorous statistical interrogation of what is, to the best of the authors' knowledge, the largest dataset ever assembled for this rare paediatric tumour.
Journal ArticleDOI
Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study
Jozsef Zsiros,Laurence Brugières,Penelope Brock,Derek J. Roebuck,Rudolf Maibach,Arthur Zimmermann,Margaret Childs,Danièle Pariente,Véronique Laithier,Jean-Bernard Otte,Sophie Branchereau,Daniel C. Aronson,Arun Rangaswami,Milind Ronghe,Michela Casanova,Michael J. Sullivan,Bruce Morland,Piotr Czauderna,Giorgio Perilongo +18 more
TL;DR: The SIOPEL-4 treatment regimen is feasible and efficacious for complete remission at the end of treatment for patients with high-risk hepatoblastoma.
Journal ArticleDOI
Improved survival with the use of adjuvant chemotherapy in the treatment of medulloblastoma.
Roger J. Packer,Leslie N. Sutton,Joel W. Goldwein,Giorgio Perilongo,Greta R. Bunin,Janis Ryan,Bruce H. Cohen,Gulio D'Angio,Eric D. Kramer,Robert A. Zimmerman,Lucy B. Rorke,Audrey E. Evans,Luis Schut +12 more
TL;DR: The results demonstrated an encouraging survival rate for children with MB/PNET, especially those treated with aggressive surgical resection followed by both radiation therapy and chemotherapy, and suggest that chemotherapy has a role for some, and possibly all, children withMB/P NET.